About

AxeroVision was founded to develop novel therapies for the treatment of Dry Eye Disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes, thus providing a more meaningful clinical benefit for patients.   

AxeroVision has assembled a nimble, highly experienced team with a combined 200+ years of experience in ophthalmic drug development at ophthalmic companies such as Allergan, Pfizer and GSK.